FDA Recalls Bevacizumab Due to Lack of Assurance of Sterility
Specialty Medicine Compounding Pharmacy is recalling repackaged Bevacizumab because sterility cannot be assured. The recall affects 2,801 doses distributed in Michigan.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: The recall is classified as FDA Class II, and the hazard involves a lack of assurance of sterility for a drug product, which poses a risk of harm even though specific injuries are not reported in the source text.
Plain-English summary
Specialty Medicine Compounding Pharmacy is recalling 2,801 doses of repackaged Bevacizumab in 0.11 mL and 0.06 mL vials. The recall was initiated because the products were compounded in the same environment and under the same practices as another product found to be non-sterile, meaning the sterility of these specific doses cannot be assured.
The affected products are prescription-only and were manufactured and distributed between July 1, 2013, and October 19, 2013. Distribution was limited to hospitals, clinics, physicians, and patients in the Michigan area. Specific lot numbers are listed in the official recall notice.
Consumers and healthcare providers should stop using the recalled products and contact the pharmacy or their healthcare provider for further instructions.
The recalled product
- Product
- Bevacizumab, (repackaged) in a) 0.11 mL and b) 0.06 mL, Rx only, Specialty Medicine Compounding Pharmacy, 350 S Lafayette, South Lyon, MI 48178
- Manufacturer
- Specialty Medicine Compounding Pharmacy
- Category
- Drug — Biologic
- Hazard
- Affected units
- 2,801
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (20)
- All unexpired lots
- manufactured and distributed between 07/01/2013 and 10/19/2013
- including Lot #s: for both sizes: 08072013@26
- 08282013@52
- 09112013@31
- 09162013@33
- 10072013@33
- 07242013@47
- 08082013@42
- 09172013@52
- 10162013@35
- 07242013@55
- 07242013@56
- 09122013@36
- 09122013@35
- 10042013@8
- 10042013@9
- 07262013@12
- 07262013@13
- 07262013@14
Distribution
Distributed in 1 state:
Part of a larger recall action
This product is one of 51 recalled by Specialty Medicine Compounding Pharmacy under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 51 products in this recall →Related recalls
Same manufacturer · Specialty Medicine Compounding Pharmacy
See all →- Severe
- SevereSpecialty Medicine Compounding Pharmacy Recalls Combo Eye Gel Due to Sterility Concerns
FDA (Drugs) · 2014-01-22
- SevereHyaluronidase Recalled Due to Lack of Assurance of Sterility
FDA (Drugs) · 2014-01-22
- SeverePhenol Injectable Recalled Due to Lack of Sterility Assurance
FDA (Drugs) · 2014-01-22
- SevereCyanocobalamin Injectable Recalled Due to Sterility Assurance Concerns
FDA (Drugs) · 2014-01-22
Same hazard · lack of sterility
See all →- HighRohto Cooling Eye Drops Max Strength Recalled Due to Sterility Concerns
FDA (Drugs) · 2026-07-29
- HighRohto Cooling Eye Drops Recalled Due to Lack of Assurance of Sterility
FDA (Drugs) · 2026-07-29
- SevereCleviprex Injectable Emulsion Recall Due to Sterility Assurance Concerns
FDA (Drugs) · 2026-07-22
- SeverePemetrexed for Injection recalled due to lack of sterility assurance
FDA (Drugs) · 2026-07-15
- SevereAzacitidine for Injection Recalled for Lack of Sterility Assurance
FDA (Drugs) · 2026-07-15